Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-05-06 09:50:37 ET Summary Regeneron is not having a great start to 2024 as the company missed Q1 revenue and EPS estimates and received two complete response letters from the FDA for odronextamab. First quarter results were negatively impacted by lower-than-expected collabora...
2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte
2024-05-03 11:15:29 ET Summary Swiss Helvetia Fund is trading at a 16% discount to NAV and could be a potential takeover target in the future. The ETF has concentrated holdings in strong businesses with high dividends, making it attractive for dividend investors. The overall d...
2024-05-03 10:28:54 ET More on Amgen Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Biggest stock movers today: WOW, AAPL, SQ, and more Amge...
2024-05-03 09:53:55 ET Summary TG Therapeutics beat first quarter revenue expectations and raised the full-year revenue guidance by $40 million at the mid-point. Work on the subcutaneous version of Briumvi continues and could represent the next step for increased long-term growth ...
2024-05-03 05:30:00 ET Summary Appleseed Fund was organized as a non-diversified series of Unified Series Trust with long-term capital appreciation as its investment objective. The Fund’s investment adviser is Pekin Singer Strauss Asset Management, Inc. Over the last six mo...
2024-05-02 07:55:40 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Barclays ...
2024-05-01 10:27:47 ET Summary Genmab's stock has lost over 35% of its value since December 2022 due to unfavorable arbitration cases and high spending on launching Epkinly. The company's top line is currently dominated by royalties from Darzalex, but it hopes Epkinly will contrib...
2024-04-28 13:00:22 ET Orphan drugs -- medicines to treat rare diseases -- from Johnson & Johnson ( NYSE: JNJ ), Roche ( OTCQX:RHHBY ), and AstraZeneca ( NASDAQ: AZN ) will allow these companies to reign as the top 3 orphan drugmakers, by sales, in 2028.... Rea...
2024-04-28 05:44:58 ET Summary Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively. Mid-single digit sales growth is expected to remain with the pipeline that it has established thus f...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options – – Additional analyses of INAVO120 will be presented in an oral abstract session at the 2024 American Society of Clinical Onc...
Roche and Hitachi High-Tech extend their long-standing partnership TOKYO, May 28, 2024 - (JCN Newswire) - Hitachi High-Tech Corporation announced that Roche and Hitachi High-Tech have extended their partnership, committing to at least 10 years of additional collaboration. Bringing t...
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for ...